Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study

Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -11% Improvement Relative Risk Famotidine for COVID-19  Wallace et al.  Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? Retrospective 7,944 patients in the USA No significant difference in mortality c19early.org Wallace et al., BMJ Open, December 2021 Favorsfamotidine Favorscontrol 0 0.5 1 1.5 2+
Famotidine for COVID-19
26th treatment shown to reduce risk in October 2021
 
*, now with p = 0.00028 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing no significant difference in mortality with famotidine use. The study provides results for use before, after, and before+after. Before+after should more accurately represent prophylaxis up to COVID-19 infection (and continued use). Before included use up to 2 years before, and after included use up to 60 days later.
Study covers metformin and famotidine.
risk of death, 11.0% higher, RR 1.11, p = 0.33, treatment 98 of 423 (23.2%), control 1,436 of 7,521 (19.1%), adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wallace et al., 31 Dec 2021, retrospective, database analysis, USA, peer-reviewed, 6 authors.
This PaperFamotidineAll
{ 'indexed': {'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T05:55:33Z', 'timestamp': 1641016533940}, 'reference-count': 33, 'publisher': 'BMJ', 'issue': '12', 'license': [ { 'start': { 'date-parts': [[2021, 12, 30]], 'date-time': '2021-12-30T00:00:00Z', 'timestamp': 1640822400000}, 'content-version': 'unspecified', 'delay-in-days': 29, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ {'name': 'Mercatus Center, George Mason University Fast Grants', 'award': ['#2207']}, { 'name': 'UC Office of the President, Emergency COVID-19 Research Seed Funding', 'award': ['R00RG3118']}, {'name': 'Mercatus Center, George Mason University Fast Grants', 'award': ['#2005']}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'short-container-title': ['BMJ Open'], 'published-print': {'date-parts': [[2021, 12]]}, 'abstract': '<jats:sec><jats:title>Objectives</jats:title><jats:p>SARS-CoV-2 enters cells using the ACE2 ' 'receptor. Medications that affect ACE2 expression or function such as angiotensin receptor ' 'blockers (ARBs) and ACE inhibitors (ACE-I) and metformin have the potential to counter the ' 'dysregulation of ACE2 by the virus and protect against viral injury. Here, we describe ' 'COVID-19 survival associated with ACE-I, ARB and metformin ' 'use.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>This is a ' 'hospital-based observational study of patients with COVID-19 infection using logistic ' 'regression with correction for pre-existing conditions and propensity score weighted Cox ' 'proportional hazards models to estimate associations between medication use and ' 'mortality.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Medical ' 'record data from the US Veterans Affairs (VA) were used to identify patients with a reverse ' 'transcription PCR diagnosis of COVID-19 infection, to classify patterns of ACE inhibitors ' '(ACE-I), ARB, beta blockers, metformin, famotidine and remdesivir use, and, to capture ' 'mortality.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>9532 ' 'hospitalised patients with COVID-19 infection followed for 60 days were ' 'analysed.</jats:p></jats:sec><jats:sec><jats:title>Outcome measure</jats:title><jats:p>Death ' 'from any cause within 60 days of COVID-19 diagnosis was ' 'examined.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Discontinuation ' 'of ACE-I was associated with increased risk of death (OR: 1.4; 95% CI 1.2–1.7). Initiating ' '(OR: 0.3; 95% CI 0.2–0.5) or continuous (OR: 0.6; 95% CI 0.5–0.7) ACE-I was associated with ' 'reduced risk of death. ARB and metformin associations were similar in direction and magnitude ' 'and also statistically significant. Results were unchanged when accounting for pre-existing ' 'morbidity and propensity score ' 'adjustment.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Recent ' 'randomised clinical trials support the safety of continuing ACE-I and ARB treatment in ' 'patients with COVID-19 where indicated. Our study extends these findings to suggest a ' 'possible COVID-19 survival benefit for continuing or initiating ACE-I, ARB and metformin ' 'medications. Randomised trials are appropriate to confirm or refute the therapeutic potential ' 'for ACE-I, ARBs and metformin.</jats:p></jats:sec>', 'DOI': '10.1136/bmjopen-2021-050051', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 12, 31]], 'date-time': '2021-12-31T15:30:28Z', 'timestamp': 1640964628000}, 'page': 'e050051', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Association of the patterns of use of medications with mortality of COVID-19 infection: a ' 'hospital-based observational study'], 'prefix': '10.1136', 'volume': '11', 'author': [ {'given': 'Arthur W', 'family': 'Wallace', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4571-4544', 'authenticated-orcid': False, 'given': 'Piera M', 'family': 'Cirillo', 'sequence': 'additional', 'affiliation': []}, {'given': 'James C', 'family': 'Ryan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nickilou Y', 'family': 'Krigbaum', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anusha', 'family': 'Badathala', 'sequence': 'additional', 'affiliation': []}, {'given': 'Barbara A', 'family': 'Cohn', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2021, 12, 31]]}, 'reference': [ { 'key': '2021123107251020000_11.12.e050051.1', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.jare.2020.03.005', 'article-title': 'COVID-19 infection: origin, transmission, and characteristics of human ' 'coronaviruses', 'volume': '24', 'author': 'Shereen', 'year': '2020', 'journal-title': 'J Adv Res'}, { 'key': '2021123107251020000_11.12.e050051.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/path.1570'}, { 'key': '2021123107251020000_11.12.e050051.3', 'first-page': '39', 'article-title': 'Short-term dexamethasone in Sars-CoV-2 patients', 'volume': '103', 'author': 'Selvaraj', 'year': '2020', 'journal-title': 'R I Med J'}, { 'key': '2021123107251020000_11.12.e050051.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NE-JMoa2007016'}, { 'key': '2021123107251020000_11.12.e050051.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/gutjnl-2020-321852'}, { 'key': '2021123107251020000_11.12.e050051.6', 'doi-asserted-by': 'crossref', 'unstructured': 'Sen Gupta PS , Biswal S , Singha D . Binding insight of clinically ' 'oriented drug famotidine with the identified potential target of ' 'SARS-CoV-2. J Biomol Struct Dyn 2020:1–7.', 'DOI': '10.26434/chemrxiv.12382265'}, { 'key': '2021123107251020000_11.12.e050051.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1053/j.gastro.2020.05.053'}, { 'key': '2021123107251020000_11.12.e050051.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Magagnoli J , Narendran S , Pereira F . Outcomes of hydroxychloroquine ' 'usage in United States veterans hospitalized with Covid-19. medRxiv ' '2020;2020.04.16.20065920.', 'DOI': '10.1101/2020.04.16.20065920'}, { 'key': '2021123107251020000_11.12.e050051.9', 'doi-asserted-by': 'crossref', 'unstructured': 'Cao YC , Deng QX , Dai SX . Remdesivir for severe acute respiratory ' 'syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. ' 'Travel Med Infect Dis 2020;101647.', 'DOI': '10.1016/j.tmaid.2020.101647'}, { 'key': '2021123107251020000_11.12.e050051.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/nejmsr2005760'}, { 'key': '2021123107251020000_11.12.e050051.11', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.20-0375'}, { 'key': '2021123107251020000_11.12.e050051.12', 'doi-asserted-by': 'publisher', 'DOI': '10.3414/me17-01-0051'}, { 'key': '2021123107251020000_11.12.e050051.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/01.RES.87.5.e1'}, { 'key': '2021123107251020000_11.12.e050051.14', 'doi-asserted-by': 'crossref', 'first-page': '185', 'DOI': '10.1007/s11684-020-0754-0', 'article-title': 'Single-cell RNA-seq data analysis on the receptor ACE2 expression ' 'reveals the potential risk of different human organs vulnerable to ' '2019-nCoV infection', 'volume': '14', 'author': 'Zou', 'year': '2020', 'journal-title': 'Front Med'}, { 'key': '2021123107251020000_11.12.e050051.15', 'doi-asserted-by': 'crossref', 'DOI': '10.1155/2012/307315', 'article-title': 'Angiotensin-converting enzyme 2: the first decade', 'volume': '2012', 'author': 'Clarke', 'year': '2012', 'journal-title': 'Int J Hypertens'}, { 'key': '2021123107251020000_11.12.e050051.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1152/ajplung.00498.2016'}, { 'key': '2021123107251020000_11.12.e050051.17', 'doi-asserted-by': 'crossref', 'first-page': '595', 'DOI': '10.1002/jmv.25726', 'article-title': 'Composition and divergence of coronavirus spike proteins and host ACE2 ' 'receptors predict potential intermediate hosts of SARS-CoV-2', 'volume': '92', 'author': 'Liu', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': '2021123107251020000_11.12.e050051.18', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/ncomms4594', 'article-title': 'Angiotensin-converting enzyme 2 protects from lethal avian influenza A ' 'H5N1 infections', 'volume': '5', 'author': 'Zou', 'year': '2014', 'journal-title': 'Nat Commun'}, { 'key': '2021123107251020000_11.12.e050051.19', 'article-title': 'Angiotensin-converting enzyme 2 inhibits lung injury induced by ' 'respiratory syncytial virus', 'volume': '6', 'author': 'Gu', 'year': '2016', 'journal-title': 'Sci Rep'}, { 'key': '2021123107251020000_11.12.e050051.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1074/jbc.M200581200'}, { 'key': '2021123107251020000_11.12.e050051.21', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s13054-017-1823-x', 'article-title': 'A pilot clinical trial of recombinant human angiotensin-converting ' 'enzyme 2 in acute respiratory distress syndrome', 'volume': '21', 'author': 'Khan', 'year': '2017', 'journal-title': 'Crit Care'}, { 'key': '2021123107251020000_11.12.e050051.22', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nature00786'}, { 'key': '2021123107251020000_11.12.e050051.23', 'doi-asserted-by': 'crossref', 'first-page': '905', 'DOI': '10.1016/j.cell.2020.04.004', 'article-title': 'Inhibition of SARS-CoV-2 infections in engineered human tissues using ' 'clinical-grade soluble human ACE2', 'volume': '181', 'author': 'Monteil', 'year': '2020', 'journal-title': 'Cell'}, { 'key': '2021123107251020000_11.12.e050051.24', 'doi-asserted-by': 'crossref', 'unstructured': 'Jarcho JA , Ingelfinger JR , Hamel MB . Inhibitors of the ' 'renin-angiotensin-aldosterone system and Covid-19. N Engl J Med 2020.', 'DOI': '10.1056/NEJMe2012924'}, { 'key': '2021123107251020000_11.12.e050051.25', 'doi-asserted-by': 'crossref', 'first-page': '275', 'DOI': '10.1016/S2213-2600(20)30558-0', 'article-title': 'Continuation versus discontinuation of renin-angiotensin system ' 'inhibitors in patients admitted to hospital with COVID-19: a ' 'prospective, randomised, open-label trial', 'volume': '9', 'author': 'Cohen', 'year': '2021', 'journal-title': 'Lancet Respir Med'}, { 'key': '2021123107251020000_11.12.e050051.26', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.25864'}, { 'key': '2021123107251020000_11.12.e050051.27', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M20-1515'}, { 'key': '2021123107251020000_11.12.e050051.28', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/hep.22399'}, { 'key': '2021123107251020000_11.12.e050051.29', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41577-020-0331-4'}, { 'key': '2021123107251020000_11.12.e050051.30', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chom.2020.04.009'}, { 'key': '2021123107251020000_11.12.e050051.31', 'doi-asserted-by': 'crossref', 'first-page': '256', 'DOI': '10.1016/j.mce.2017.09.025', 'article-title': 'Metformin improves obesity-associated inflammation by altering ' 'macrophages polarization', 'volume': '461', 'author': 'Jing', 'year': '2018', 'journal-title': 'Mol Cell Endocrinol'}, { 'key': '2021123107251020000_11.12.e050051.32', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.isci.2020.101425', 'article-title': 'ACE2, metformin, and COVID-19', 'volume': '23', 'author': 'Malhotra', 'year': '2020', 'journal-title': 'iScience'}, { 'key': '2021123107251020000_11.12.e050051.33', 'doi-asserted-by': 'crossref', 'DOI': '10.26633/RPSP.2020.40', 'article-title': 'Clinical trials on drug repositioning for COVID-19 treatment', 'volume': '44', 'author': 'Rosa', 'year': '2020', 'journal-title': 'Rev Panam Salud Publica'}], 'container-title': ['BMJ Open'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmjopen-2021-050051', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 31]], 'date-time': '2021-12-31T15:30:42Z', 'timestamp': 1640964642000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12]]}, 'references-count': 33, 'journal-issue': { 'issue': '12', 'published-online': {'date-parts': [[2021, 12, 31]]}, 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['10.1136/bmjopen-2021-050051'], 'URL': 'http://dx.doi.org/10.1136/bmjopen-2021-050051', 'relation': {}, 'ISSN': ['2044-6055', '2044-6055'], 'issn-type': [{'value': '2044-6055', 'type': 'print'}, {'value': '2044-6055', 'type': 'electronic'}], 'subject': ['General Medicine'], 'published': {'date-parts': [[2021, 12]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit